MedPath

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Recruiting
Conditions
Liver Diseases
Registration Number
NCT05264051
Lead Sponsor
University of Chicago
Brief Summary

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Detailed Description

Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam.

Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated.

1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation.

2. Pts. with hepatobiliary neoplasia

3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement

4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1200
Inclusion Criteria
  • Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated
Exclusion Criteria
  • <18 yrs. of age

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Waitlist MortalityMeasured up to 10 years out from enrollment

Death prior to liver transplant or delisting from enrollment in the study

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The University of Chicago

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath